3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Pheochromocytoma
1
Paraganglioma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms
1
Meningioma
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Radiotherapy
3
Nivolumab
3
pembrolizumab
2
Temozolomide
2
Surveys and Questionnaires
2
Paclitaxel
2
ONC206
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
Etoposide
2
Cyclophosphamide
2
Carboplatin
2
Biopsy
2
regorafenib
1
pegfilgrastim
1
mirdametinib
1
lutetium Lu 177 dotatate
1
fludarabine
1
etoposide phosphate
1
entrectinib
1
entinostat
1
elacestrant
1
decitabine and cedazuridine drug combination
1
cabozantinib
1
amino-acid, glucose, and electrolyte solution
1
alectinib
1
aflibercept
1
abemaciclib
1
Topotecan
1
Tissue Banks
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Central Nervous System Neoplasms
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled